Transaction · 0001835966-26-000006

Sandler Alan B.

Sandler Alan B., CDO, reported an open-market or private sale at Revolution Medicines, Inc. involving 336.000000 shares for an estimated $66965.88. Reported holdings after the transaction were 52868.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCDO
RVMDRevolution Medicines, Inc.
Trade date
Sep 16, 2026
Filing date
Sep 18, 2026
View on SEC Insider profile
Disclosed value-$66.9kShares × reported price
Shares traded336$199.30 per share
Holdings after52.8kDirect
% of reported position traded0.63%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 53,204 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

RVMD price since this filing

Daily closing prices, with the filing date and available return windows
RVMD · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +11.0%1w ago +8.8%1d ago +7.3%
Returns since7d +7.3%30d -6.8%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001835966-26-000006
Common Stock
Transaction date
Sep 16, 2026
Filed Sep 18, 2026, 10:06 PM · 2d delay
Shares
336 sh
$199.30 per share
Estimated value
-$66.9k
Computed from shares × price
Holdings after
52,868 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Development Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 13, 2026 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

  2. F2

    Includes 209 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

  3. F3

    Includes 52,350 restricted stock units.

Original filing · 0001835966-26-000006
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

RVMD